Merck and Moderna show promise in late-stage personalized cancer vaccine trial
Merck and Moderna announced positive initial results from their first-ever late-stage trial of an experimental personalized cancer vaccine. The treatment lowered the risk of cancer spreading to distant parts of the body, building on earlier Phase 2 data. The companies plan to present results at an international medical meeting and begin discussions with regulators, with U.S. filing timing unclear.
Coverage (7)
- Moderna, Merck breakthrough could usher in cancer vaccines (crossroadstoday.com)
- Moderna, Merck breakthrough could usher in wave of cancer vaccines (cnn.com)
- Moderna, Merck vaccine cuts recurrence and spread of melanoma, raising new treatment hope (reuters.com)
- Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma (nbcnews.com)
- Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma (biopharmadive.com)
- Moderna and Merck say melanoma vaccine succeeded in large trial (cnn.com)
- Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar (cnbc.com)